First-line tepotinib for a very elderly patient with metastatic NSCLC harboring MET exon 14 skipping mutation and high PD-L1 expression.

IF 2 Q3 PHARMACOLOGY & PHARMACY
Drug Target Insights Pub Date : 2023-10-06 eCollection Date: 2023-01-01 DOI:10.33393/dti.2023.2626
Alessandro Inno, Giuseppe Bogina, Giulio Settanni, Matteo Salgarello, Giovanni Foti, Carlo Pomari, Vincenzo Picece, Stefania Gori
{"title":"First-line tepotinib for a very elderly patient with metastatic NSCLC harboring <i>MET</i> exon 14 skipping mutation and high PD-L1 expression.","authors":"Alessandro Inno,&nbsp;Giuseppe Bogina,&nbsp;Giulio Settanni,&nbsp;Matteo Salgarello,&nbsp;Giovanni Foti,&nbsp;Carlo Pomari,&nbsp;Vincenzo Picece,&nbsp;Stefania Gori","doi":"10.33393/dti.2023.2626","DOIUrl":null,"url":null,"abstract":"<p><p>Optimal treatment for metastatic non-small cell lung cancer (NSCLC) with mesenchymal epithelial transition gene (<i>MET</i>) exon 14 skipping mutation has not been established yet. MET inhibitors were demonstrated to be effective and tolerated in patients with this condition, while evidence on safety and efficacy of immunotherapy and/or chemotherapy in this population is limited. Here we report the case of an 86-year-old male with metastatic NSCLC harboring <i>MET</i> exon 14 skipping mutation and with high programmed cell death ligand 1 (PD-L1) expression (tumor proportion score ≥50%). The patient received the MET inhibitor tepotinib as first-line treatment, achieving a partial response, with G2 peripheral edema as adverse event that was successfully managed with temporary discontinuation, dose reduction, diuretics and physical therapy. After 31 months, the patient is still receiving tepotinib, with an ongoing response. Tepotinib is a valuable therapeutic option for first-line treatment of older patients with NSCLC harboring <i>MET</i> exon 14 skipping mutation, even in the presence of high PD-L1 expression.</p>","PeriodicalId":11326,"journal":{"name":"Drug Target Insights","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2023-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fc/1e/dti-17-110.PMC10568218.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Target Insights","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33393/dti.2023.2626","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Optimal treatment for metastatic non-small cell lung cancer (NSCLC) with mesenchymal epithelial transition gene (MET) exon 14 skipping mutation has not been established yet. MET inhibitors were demonstrated to be effective and tolerated in patients with this condition, while evidence on safety and efficacy of immunotherapy and/or chemotherapy in this population is limited. Here we report the case of an 86-year-old male with metastatic NSCLC harboring MET exon 14 skipping mutation and with high programmed cell death ligand 1 (PD-L1) expression (tumor proportion score ≥50%). The patient received the MET inhibitor tepotinib as first-line treatment, achieving a partial response, with G2 peripheral edema as adverse event that was successfully managed with temporary discontinuation, dose reduction, diuretics and physical therapy. After 31 months, the patient is still receiving tepotinib, with an ongoing response. Tepotinib is a valuable therapeutic option for first-line treatment of older patients with NSCLC harboring MET exon 14 skipping mutation, even in the presence of high PD-L1 expression.

一线替波替尼用于一名患有转移性NSCLC的高龄患者,该患者携带MET外显子14跳跃突变和高PD-L1表达。
间充质-上皮转化基因(MET)第14外显子跳跃突变治疗转移性癌症(NSCLC)的最佳方案尚未确定。MET抑制剂已被证明对这种情况的患者有效且耐受,而免疫疗法和/或化疗在该人群中的安全性和有效性证据有限。在此,我们报告了一例86岁男性转移性非小细胞肺癌,其携带MET外显子14跳跃突变,并具有高程序性细胞死亡配体1(PD-L1)表达(肿瘤比例得分≥50%)。患者接受MET抑制剂替波替尼作为一线治疗,获得部分缓解,G2外周水肿作为不良事件,通过暂时停药、减少剂量、利尿剂和物理治疗成功控制。31个月后,患者仍在接受替波替尼治疗,并有持续的反应。替泊替尼是一线治疗携带MET外显子14跳跃突变的老年NSCLC患者的一种有价值的治疗选择,即使在PD-L1高表达的情况下也是如此。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Drug Target Insights
Drug Target Insights PHARMACOLOGY & PHARMACY-
CiteScore
2.70
自引率
0.00%
发文量
5
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信